Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT

Jaime Sanz*, Myriam Labopin, Goda Choi, Alexander Kulagin, Jacopo Peccatori, Jan Vydra, Péter Reményi, Jurjen Versluis, Montserrat Rovira, Didier Blaise, Hélène Labussière-Wallet, Juan Montoro, Simona Sica, Ellen Meijer, Maija Itälä-Remes, Nicolaas Schaap, Claude Eric Bulabois, Simona Piemontese, Mohamad Mohty, Fabio Ciceri

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)


There is a paucity of information on how to select the most appropriate unrelated donor (UD) in hematopoietic stem cell transplantation (HSCT) using posttransplant cyclophosphamide (PTCy). We retrospectively analyzed the characteristics of 10/10 matched UDs (MUDs) and 9/10 mismatched UDs (MMUDs) that may affect transplant outcomes in patients with acute myeloid leukemia (AML) in first or second complete remission (CR1 or CR2). The primary end point was leukemia-free survival (LFS). Overall, 1011 patients were included with a median age of 54 years (range, 18-77). Donors had a median age of 29 years (range, 18-64); 304 (30%) were females, of which 150 (15% of the whole group) were donors to male recipients, and 621 (61%) were MUDs; 522 (52%) had negative cytomegalovirus (CMV-neg) serostatus, of which 189 (19%) were used for CMV-neg recipients. Donor age older than 30 years had a negative impact on relapse (hazard ratio [HR], 1.38; 95% confidence interval [CI], 1.06-1.8), LFS (HR, 1.4; 95% CI, 1.12-1.74), overall survival (HR 1.45; 95% CI, 1.14-1.85) and graft-versus-host disease (GVHD) free, relapse-free survival (HR, 1.29; 95% CI, 1.07-1.56). In addition, CMV-neg donors for CMV-neg recipients were associated with improved LFS (HR, 0.74; 95% CI, 0.55-0.99). The use of MMUD and female donors for male recipients did not significantly impact any transplant outcomes. For patients undergoing HSCT from a UD with PTCy for AML, donor age <30 years significantly improves survival. In this context, donor age might be prioritized over HLA match considerations. In addition, CMV-neg donors are preferable for CMV-neg recipients. However, further research is needed to validate and refine these recommendations.

Original languageEnglish
Pages (from-to)2534-2543
Number of pages10
Issue number24
Publication statusPublished - 29 Mar 2024

Bibliographical note

Publisher Copyright:
© 2024 American Society of Hematology


Dive into the research topics of 'Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT'. Together they form a unique fingerprint.

Cite this